Skip to main content

Table 2 Response of angiomyolipoma volume to everolimus therapy

From: Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial

  3 months 6 months 12 months 18 months 24 months
Patients (n) 18 17 15 15 14
No. of response (n,%) 9 (52.94%) 10 (58.82%) 10 (66.67%) 5(33.33%) 1(7.14%)
a% of baseline value (Mean ± SD,%) 47.73 ± 19.81 44.27 ± 23.69 41.14 ± 26.54 60.67 ± 23.28 77.62 ± 16.66
P value for change from baseline value 0.002 0.002 <0.001 0.006 0.014
  1. athe average percentage change of baseline in the total volume of all target AML lesions